Stockscreener 앱 받기
2.63
1.50%
-0.04
시장 영업 전:
2.68
0.05
+1.90%
전일 마감가:
$2.67
열려 있는:
$2.63
하루 거래량:
39,740
Relative Volume:
0.77
시가총액:
$24.67M
수익:
$2.14M
순이익/손실:
$-15.44M
주가수익비율:
-0.8499
EPS:
-3.0946
순현금흐름:
$-24.67M
1주 성능:
-5.40%
1개월 성능:
-34.25%
6개월 성능:
-37.38%
1년 성능:
-89.46%
1일 변동 폭
$2.57
$2.69
1주일 범위
$2.57
$2.895
52주 변동 폭
$2.57
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
명칭
Tvardi Therapeutics Inc
전화
(713) 489-8654
주소
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Compare TVRD vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
2.63 | 25.05M | 2.14M | -15.44M | -24.67M | -3.0946 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-10-14 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-10-14 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | 개시 | Barclays | Overweight |
| 2025-10-13 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | 개시 | Raymond James | Outperform |
| 2025-07-11 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-06-12 | 개시 | Piper Sandler | Overweight |
| 2025-05-21 | 개시 | Oppenheimer | Outperform |
| 2025-05-15 | 개시 | BTIG Research | Buy |
| 2024-06-13 | 다운그레이드 | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | 다운그레이드 | Needham | Buy → Hold |
| 2024-06-13 | 다운그레이드 | Stifel | Buy → Hold |
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
모두보기
Tvardi Therapeutics Inc 주식(TVRD)의 최신 뉴스
Tvardi Therapeutics (TVRD) Slides as Stock Approaches Key Support Near $2.51Fibonacci Time Zone - newsline.com
TVRD Q1 2026 Earnings: Narrowed Loss Per Share Beats Expectations Amid Pipeline ProgressHealthcare Earnings Report - newsline.com
Tvardi Therapeutics Shareholders Approve Directors and Governance Measures - TipRanks
Tvardi Therapeutics (TVRD) grants 6,000 stock options to director - Stock Titan
Tvardi Therapeutics (TVRD) director granted 6,000 options at $2.78 exercise price - Stock Titan
Tvardi Therapeutics (TVRD) director Sujal Shah awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director receives grant of 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) director awarded 6,000 stock options at $2.78 - Stock Titan
Tvardi Therapeutics (TVRD) investors approve directors, say-on-pay and Deloitte as 2026 auditor - Stock Titan
Tvardi Therapeutics (TVRD) Declines 2.88% as Stock Tests Key Support; Near-Term Outlook Hinges on $2.56 FloorFactor Momentum - newsline.com
This Cerebras Systems analyst begins coverage on a bullish note; here are top 3 initiations for Monday - MSN
H.C. Wainwright initiates Tvardi Therapeutics stock with buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright initiates Tvardi Therapeutics stock with buy rating - Investing.com
HC Wainwright Initiates Tvardi Therapeutics at Buy With $9 Price Target - Moomoo
H.C. Wainwright Initiates Tvardi Therapeutics(TVRD.US) With Buy Rating, Announces Target Price $9 - Moomoo
Tvardi Therapeutics: STAT3 inhibitor TTI-109 aims to address fibrosis and immune disorders, with key data expected soon - TradingView
Tvardi Therapeutics: STAT3 inhibitor programs advance with new data expected, targeting fibrosis and immune disorders - TradingView
MSN Money - MSN
TVRD Q1 2026 Earnings: Net Loss Narrows as Clinical Pipeline AdvancesEarnings Beat Streak - newsline.com
Ocugen, Assertio among healthcare stocks set to join Russell Microcap; Definium Therapeutics, Tvardi Therapeutics to exit - MSN
Tvardi Therapeutics (TVRD) Declines 4%: Support at $3.18 in FocusVWAP Deviation - newsline.com
Tvardi Therapeutics (TVRD) Holds Steady Near Support Amid Low-Volume TradingShort Setup Alerts - The Legal Advocate
Tvardi Therapeutics Q1 2026 Earnings: Narrower-than-expected loss as pipeline advancesEarnings Manipulation Risk - Newser
Tvardi Therapeutics to Participate in Upcoming Investor Events - GlobeNewswire
Tvardi Therapeutics (TVRD) Trading at $4.00 — Key Decision Point 2026-05-18Institutional Volume - The Legal Advocate
What Tvardi Therapeutics (TVRD)'s +1.01% Jump Means for Investors 2026-05-17Market Neutral Pair - Newser
[EFFECT] Tvardi Therapeutics, Inc. SEC Filing - Stock Titan
Cantor Fitzgerald Sticks to Their Hold Rating for Tvardi Therapeutics (TVRD) - The Globe and Mail
Barclays Maintains Tvardi Therapeutics(TVRD.US) With Sell Rating, Maintains Target Price $3 - Moomoo
Number of shareholders of Tvardi Therapeutics, Inc. – NASDAQ:TVRD - TradingView
593,758 resale shares by Tvardi Therapeutics (NASDAQ: TVRD) post‑merger - Stock Titan
Tvardi Therapeutics 4Q Research and Development Expenses $4.9M >TVRD - Moomoo
Tvardi Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Tvardi Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Tvardi Therapeutics 1Q 2026: Revenue ($6.81M), Net income ($6.8M), EPS ($0.73) — 10-Q Summary - TradingView
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update - The Manila Times
Tvardi Therapeutics: Net loss narrowed to $6.8M, but continued operations depend on securing additional funding - TradingView
Tvardi Therapeutics: Net loss narrowed in Q1 2026 as clinical milestones for TTI-109 and TTI-101 approach - TradingView
Tvardi: Q1 Earnings Snapshot - marketscreener.com
Tvardi Therapeutics (NASDAQ: TVRD) posts Q1 2026 loss and warns on going concern - Stock Titan
Tvardi Therapeutics (NASDAQ: TVRD) narrows Q1 loss and targets 2026 STAT3 trial readouts - Stock Titan
Two biotech readouts ahead as Tvardi says cash lasts into Q4 - Stock Titan
Tvardi Therapeutics Inc (TVRD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.27%
1.43%
자본화:
|
볼륨(24시간):